Posted on 04/09/2020 7:07:00 AM PDT by SeekAndFind
NEWS RELEASE
A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee.
The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease study, or ORCHID Study, is being conducted by the Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network of the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
The first participants have enrolled in the trial at Vanderbilt University Medical Center, Nashville, one of dozens of centers in the PETAL Network. The blinded, placebo-controlled randomized clinical trial aims to enroll more than 500 adults who are currently hospitalized with COVID-19 or in an emergency department with anticipated hospitalization. All participants in the study will continue to receive clinical care as indicated for their condition. Those randomized to the experimental intervention will also receive hydroxychloroquine.
“Effective therapies for COVID-19 are urgently needed,” said James P. Kiley, director, Division of Lung Diseases, NHLBI. “Hydroxychloroquine has showed promise in a lab setting against SARS-CoV-2, the virus that causes COVID-19 and preliminary reports suggest potential efficacy in small studies with patients. However, we really need clinical trial data to determine whether hydroxychloroquine is effective and safe in treating COVID-19.”
While COVID-19 usually presents as an acute respiratory infectious illness, it can damage multiple organ systems, including heart, lung, and blood. Most adults with COVID-19 experience fever, cough, and fatigue and then recover within one to three weeks. However, some develop severe illness, typically manifesting as pneumonia and respiratory failure, with continued progression to acute respiratory distress syndrome and death. Currently, no therapies have been demonstrated to prevent the progression of COVID-19 to severe illness, but several medicines available in the United States have been proposed as potential therapies.
Hydroxychloroquine is used to treat malaria and rheumatoid conditions such as arthritis. In various studies, the drug has demonstrated antiviral activity, an ability to modify the activity of the immune system, and has an established safety profile at appropriate doses, leading to the hypothesis that it may also be useful in the treatment of COVID-19. The drug is not without risks as even short term use can cause cardiac arrythmias, seizures, dermatological reactions, and hypoglycemia.
“Many U.S. hospitals are currently using hydroxychloroquine as first-line therapy for hospitalized patients with COVID-19 despite extremely limited clinical data supporting its effectiveness,” said Wesley Self, M.D., M.P.H., emergency medicine physician at Vanderbilt University Medical Center and PETAL Clinical Trials Network investigator leading the ORCHID trial. “Thus, data on hydroxychloroquine for the treatment of COVID-19 are urgently needed to inform clinical practice.”
COVID-19 cases were first identified in December 2019 in Wuhan, Hubei Province, China. As of April 8, 2020, the World Health Organization (WHO) has reported more than 1.3 million cases of COVID-19 and more than 79,000 deaths worldwide, and the Centers for Disease Control and Prevention has reported more than 395,000 confirmed COVID-19 cases and 12,700 deaths in the United States.
ORCHID participants will be randomly assigned to receive hydroxychloroquine 400 mg twice daily for two doses (day one), then 200 mg twice daily for the subsequent eight doses (days two to five) or a placebo twice daily for five days.
NIH also recently launched a trial to study Remdesivir as a possible treatment for COVID-19. That clinical trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) [NCT04280705]. These two trials will provide data on the effectiveness and safety of each agent versus placebo in the urgent race to find effective therapies for treating COVID-19.
And what happens to some poor, dying person in the control group whose only hope is Hydroxychloroquine? In the genuine tradition of Zeke Emanuel, MD, and Doktor Jopsef Mengele, that poor person will be left to choke and die in her own mucous secretions while being “comfortably and humanely” treated with the good doktors standing around and taking careful notes.
“My nephew, 50 years old, overweight and diabetic, was admitted to the ICU Friday with Wuhan plague. He was given this “unproven” drug the next day. He is scheduled to be released in two days. Thank God his doctors gave him the drug rather than a fatal case of TDS.”
Even viewing his case in purely economic terms, his doctors made the absolutely right decision, given how much it would have cost the taxpayers/insurance to keep him in the hospital, put him on a respirator, and wait for him to die, the very “treatment” Zeke Emanuel and the other DemonShits recommend.
“NIH also recently launched a trial to study Remdesivir as a possible treatment for COVID-19.”
My point, which I should have stated instead of assuming the reader would make the connection, is that they are giving the new, more costly drug, preference over the partially proven cheap drug with political overtones.
i got your point. The be point I am making is while everyone is focused on the cheap drug it is not a miracle or necessarily the best treatment. It is an arrow in the quiver but real studies are being done and finding encouraging results in treating critical patients. They are looking better than the cheaper alternative which doesn’t appear to have much to offer hosptalized patients. The ones not in the hospital do fine anyway so we need to see if it’s worth the risk of exposing them to a drug with side effects to treat something they will get over in their own anyway. I don’t know the answer to that yet.
I looked at the study details, there is no effing mentioning of Zn as part of medication being administered to the COVID19 patients. If that’s the case, the whole study is doomed, if not by design, then by sheer incompetence, The active element of replicase inhibition is Zn ion, not HCQ (which serves as simple ionophore for Zn). I pray I am wrong and if I’m not, then the whole medical establishment are a bunch of criminals.
“I see no mention of Dr. Zelenko’s cocktail of hydroxychloroquine, zinc sulfate and azithromycin. NIH fiddles while the Wuhan virus burns.”
Dr. Zelenko says that an adequate supply of zinc is necessary for the hydroxychloroquine to be effective. I don’t know if Dr. Zelenko is correct about this, but let’s assume, for the sake of argument, that he is correct. If so, then the NIH study could actually be counterproductive, because it could show hydroxychloroquine to be ineffective, when in reality it just needs to be co-administered with zinc. Thousands of lives could be lost because of an impaired study.
You’re exactly right. Dr. Zelenko’s cocktail works and NIH would be wise to use his protocol if they’re serious about their clinical trial.
All the people who condemned Trump over this, promise me that you will never ever take this drug, no matter what.
What happened to the New York study that was to begin 2 weeks ago????
What happened to the New York study that was to begin 2 weeks ago????
==
Yeah....those were supposed to start on Mar 23.....where’s the update, CuCu Cuomo????
I agree.
All a bunch of nonsense.
Headed up by Fauch and Dr Scarf and their connections.
MUST WATCH VIDEO!
Dr. Zelenko update! Inspiring! Watch the WHOLE THING! Full of nuggets spread throughout. Also Dr. Karladine Graves with additional info and perspective.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.